Theralase Technologies Inc. designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

1. Press Release
Theralase Launches New Head Office and Therapeutic Laser Centre
Toronto, ON – May 28, 2013 - Theralase Technologies Inc. (TSX-V: TLT), announced today the launch of
its new head office and multidisciplinary therapeutic laser centre in the heart of the Beach District of
Toronto, Ontario. The new laser centre will provide local patients with a proven, highly effective, non-
invasive treatment to address painful and inflamed medical conditions, without the need for surgery or
pharmaceutical drugs, and their associated side effects.
“The Centre will be a multidisciplinary pain and rehabilitation treatment centre focused on delivering
Theralase therapeutic laser therapy treatments through mainstream medical practitioners, such as:
medical doctors, chiropractors, physical therapists, naturopathic doctors, doctors of podiatry and
registered massage therapists,” said Dr. Rhonda Mostyn, Clinic Director of Theralase Therapeutic Laser
Centre. “Our initial focus will be primarily chronic and acute pain caused by neural muscular skeletal
conditions, sports injuries, motor vehicle accidents or trauma, but as the centre grows, we may branch
out into other disciplines such as wound healing and addiction.”
“With regards to our growing number of customers, the new training facility will provide state of the
art conferencing technology and training sessions on our cutting-edge technology, laser therapy
certification courses and the latest treatment protocol optimization support,” said Roger Dumoulin
White, President and CEO of Theralase Technologies. “The new corporate head office, in addition to
housing executive management, finance, sales and marketing functions will also support an ISO-13485
certified, Health Canada, FDA and CE approved facility to manufacture the Theralase line of therapeutic
lasers, as well as aftermarket sales and service support for all of Theralase’s healthcare customers.
Thousands of satisfied healthcare practitioners and patients throughout North America attest to the
safety and effectiveness of Theralase’s laser technology. We expect the laser centre to be very
successful in the near term adding a significant revenue stream to the Company.”
The corporate head office and therapeutic laser centre will now be located at, 1945 Queen Street East,
Toronto, Ontario, Canada, M4L 1H7, Phone: 416-699-LASE (5273), Toll-free: 1-866-843-LASE (5273),
Fax: 416-699-5250, and will be open from 7:00 am to 7:00 pm 7 days a week to fully service our local
patients and our international sales team.
About Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase
technology is safe and effective in treating pain, inflammation and for tissue regeneration of neuro
musculoskeletal conditions and wound healing. Theralase is currently developing proprietary Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when
light activated by Theralase’s proprietary and patented laser technology.
For further information please visit www.theralase.com , regulatory filings may be viewed by visiting
www.sedar.com.

2. Press Release
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 242
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com